Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

BACKGROUND: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. OBJECTIVE: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mult Scler
Main Authors: Comi, Giancarlo, Alroughani, Raed, Boster, Aaron L, Bass, Ann D, Berkovich, Regina, Fernández, Óscar, Kim, Ho Jin, Limmroth, Volker, Lycke, Jan, Macdonell, Richard AL, Sharrack, Basil, Singer, Barry A, Vermersch, Patrick, Wiendl, Heinz, Ziemssen, Tjalf, Jacobs, Alan, Daizadeh, Nadia, Rodriguez, Claudio E, Traboulsee, Anthony
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2019
Assuntos:
Original Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7720359/
https://ncbi.nlm.nih.gov/pubmed/31762387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458519888610
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados